加载中
NASDAQHealthcareMedical - Pharmaceuticals
最新数据
US$8.32
+US$0.54 · +6.94%
Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.
常规交易时段
US$8.32
+US$0.54 · +6.94%
盘中时间采用ET。市场数据可能有所延迟。
Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.
日内区间
当前US$8.32
52周区间
当前US$8.32
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
60
合理估值
情绪
51
多空交织
风险
57
风险偏高
动量
56
中性
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.
日内区间
当前US$8.32
52周区间
当前US$8.32
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 6202 USD | — | — | — | — |
| 销货成本 | 6318 USD | — | — | — | — |
| 毛利 | −116 USD | — | — | — | — |
| 研究与开发 | 92.39万 USD | 14.44万 USD | 7.21万 USD | — | — |
| 销售、一般及管理费用 | 1842.73万 USD | 106.65万 USD | 134万 USD | 97.63万 USD | 2.78万 USD |
| 营业费用 | 1935.12万 USD | 121.09万 USD | 134万 USD | 97.63万 USD | 2.55万 USD |
| 利息收入 | — | 54.87万 USD | 581.3万 USD | 431.66万 USD | — |
| 利息支出 | 853.13万 USD | 9.8万 USD | 8966 USD | — | — |
| 折旧和摊销 | 801.94万 USD | — | 134.02万 USD | — | 2.78万 USD |
| 营业利润 | −1935.13万 USD | −121.09万 USD | −134万 USD | −97.63万 USD | −2.55万 USD |
| 净利润 | −2448.08万 USD | −130.99万 USD | 446.4万 USD | 334.02万 USD | −2.55万 USD |
公司数据更新于 2026年10月13日。
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
